一项在欧洲和中国进行的新型胃泌素释放肽前体(ProGRP)免疫检测多中心评估研究
一项在欧洲和中国进行的新型胃泌素释放肽前体(ProGRP)免疫检测多中心评估研究
About this item
Full title
Author / Creator
Publisher
The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands%University Hospital Bonn and Center of Integrative Oncology Cologne/Bonn, Sigmund-Freud-Strasse, Bonn 25-53127, Germany%Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, China%Peking Union Medical College Hospital (PUMCH), 1Shuaifuyuan, Dongcheng District, Beijing 100730, China%Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany%Hospital Clinic, University of Barcelona, Carrer Villarroel 170, Barcelona 08036, Spain
Journal title
Language
Chinese
Formats
Publication information
Publisher
The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands%University Hospital Bonn and Center of Integrative Oncology Cologne/Bonn, Sigmund-Freud-Strasse, Bonn 25-53127, Germany%Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, China%Peking Union Medical College Hospit...
More information
Scope and Contents
Contents
背景在欧洲和中国进行Elecsys?胃泌素释放肽前体(ProGRP)免疫检测的多中心评估研究.方法在欧洲的3个中心和中国的2个中心,在肺癌中,通过不精密度、稳定性、方法学比较和鉴别诊断能力来评价该检测法.结果5个分析物浓度的中间不精密度范围为变异系数:2.2%-6.0%.在不同储存条件下,血浆和血清样本均显示出良好的稳定性.在血浆中Elecsys?和ARCHITECT检测(斜率1.02,截距-2.72 pg/mL)之间表现出良好的相关性.同时,Elecsys?检测在血清和血浆样本之间表现出良好的相关性(斜率0.93,截距2.35 pg/mL;相关系数0.97).ProGRP作为不受种族、年龄、性别或吸烟史相关影响的检测手段,可鉴别小细胞和非小细胞肺癌(NSCLC);截断值为84 pg/mL时...
Alternative Titles
Full title
一项在欧洲和中国进行的新型胃泌素释放肽前体(ProGRP)免疫检测多中心评估研究
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_wanfang_journals_zgfazz201708013
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_wanfang_journals_zgfazz201708013
Other Identifiers
ISSN
1009-3419
DOI
10.3779/j.issn.1009-3419.2017.08.12
